Adenocarcinoma of the Rectum Recruiting Phase 2 Trials for Tucatinib (DB11652)

IndicationStatusPhase
DBCOND0028688 (Adenocarcinoma of the Rectum)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03043313Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal CancerTreatment